DDInter1141 DDInter1082
17-Hydroxy-6-methylpregna-3,6-diene-3,20-dione. A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Megestrol acetate {u} (Compound) resembles {v} (Compound) Dydrogesterone
Megestrol acetate {u} (Compound) resembles {v} (Compound) Methyltestosterone
Megestrol acetate {u} (Compound) binds {v} (Gene) PGR
Megestrol acetate {u} (Compound) palliates {v} (Disease) breast cancer
Megestrol acetate {u} (Compound) is included by {v} (Pharmacologic Class) Progesterone Congeners
Megestrol acetate (Compound) resembles Dydrogesterone (Compound)
Megestrol acetate (Compound) resembles Methyltestosterone (Compound)
Megestrol acetate (Compound) binds PGR (Gene)
Megestrol acetate (Compound) palliates breast cancer (Disease)
Megestrol acetate (Compound) is included by Progesterone Congeners (Pharmacologic Class)